CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 (SKU: B2173, APExBIO) is a nanomolar potency, ATP-competitive inhibitor of PDGFRα and PDGFRβ, exhibiting high selectivity over major kinases such as VEGFR and EGFR (Pladevall-Morera et al., 2022). Its in vivo efficacy includes >50% reduction in PDGFR-β phosphorylation and 70–90% inhibition of PDGF-BB-induced angiogenesis in rodent models. CP-673451 is cell-permeable, effective in ATRX-deficient glioma, and demonstrates robust tumor growth suppression in multiple xenograft models. It is a reference compound for dissecting PDGFR signaling and optimizing angiogenesis inhibition workflows (APExBIO product page). Storage and solubility parameters are well-characterized for reproducible experimental use.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases that regulate cell proliferation, survival, and angiogenesis. Aberrant PDGFR signaling is implicated in oncogenesis, particularly in high-grade gliomas and other solid tumors (Pladevall-Morera et al., 2022). Loss-of-function mutations in ATRX, a chromatin remodeler and tumor suppressor, are frequently observed in these cancers and are associated with PDGFR amplification and altered therapy response. Inhibition of PDGFR activity is a validated approach to suppress tumor angiogenesis and growth. Selective, potent inhibitors like CP-673451 provide precise tools for dissecting these signaling pathways in vitro and in vivo.

Mechanism of Action of CP-673451

CP-673451 is an ATP-competitive inhibitor that binds to the kinase domain of PDGFRα and PDGFRβ, preventing autophosphorylation and downstream signaling. It exhibits IC₅₀ values of 10 nM for PDGFRα and 1 nM for PDGFRβ in biochemical assays. Selectivity profiling demonstrates pronounced inhibition of PDGFRs, with minimal activity against related kinases: VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR are not significantly inhibited at <1 μM concentrations. Moderate inhibition of c-Kit is observed (IC₅₀ = 1.1 μM), indicating >180-fold selectivity over c-Kit in relevant cell lines. Cellular studies confirm robust PDGFR-β inhibition (IC₅₀ = 6.4 nM in PAE-β cells). By blocking PDGFR activity, CP-673451 suppresses proliferation, migration, and angiogenic processes in tumor and endothelial cells.

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-α and PDGFR-β with IC₅₀ values of 10 nM and 1 nM, respectively, in in vitro kinase assays (APExBIO).
• Demonstrates >180-fold selectivity for PDGFR-β over c-Kit in H526 cell models (APExBIO).
• Oral dosing at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFR-β phosphorylation by >50% for at least 4 hours (Pladevall-Morera et al., 2022).
• Suppresses PDGF-BB-induced angiogenesis by 70–90% in mouse sponge angiogenesis assays (APExBIO).
• Inhibits tumor growth and reduces microvessel density in Colo205, LS174T, H460, and U87MG xenograft models (Pladevall-Morera et al., 2022).
• ATRX-deficient high-grade glioma cells exhibit increased sensitivity to CP-673451 and other PDGFR inhibitors, supporting its use in precision oncology research (Pladevall-Morera et al., 2022).

For a deeper mechanistic analysis of CP-673451 in ATRX-deficient glioma models, see this article; the current article extends the discussion with granular kinetic and in vivo benchmarks. For application-focused guidance on workflow reliability, this Q&A-based guide provides scenario-driven advice, while this article emphasizes quantitative selectivity and cross-model reproducibility. For a comparison of selectivity data and implementation tips, see also this PD-L1.info article—here, we update with the latest IC₅₀ and storage data.

Applications, Limits & Misconceptions

CP-673451 is primarily used in preclinical cancer research. It enables precise modulation of PDGFR signaling in cell lines and animal models. Applications include:

• Evaluating PDGFR-driven proliferation and migration in cancer and endothelial cells.
• In vivo angiogenesis inhibition and tumor growth suppression assays.
• Dissecting ATRX-dependent responses in glioblastoma and other tumors.
• Benchmarking selectivity and potency in kinase inhibitor panels.

Common Pitfalls or Misconceptions

• Not effective against VEGFR, EGFR, or TIE-2 at standard concentrations: CP-673451 is highly selective for PDGFRs and should not be used as a broad-spectrum RTK inhibitor.
• Moderate inhibition of c-Kit may confound studies in c-Kit-expressing models: Use with caution in settings where c-Kit activity is critical.
• Water insolubility requires careful solvent selection: Stock solutions should be prepared in DMSO or ethanol, not aqueous buffers.
• Short-term stability of working solutions: Solutions in DMSO should be used promptly or stored at -20°C for limited periods to prevent degradation.
• Not a clinically approved therapeutic: For research use only; not validated for human or veterinary therapy.

Workflow Integration & Parameters

CP-673451 is supplied as a solid compound (C₂₄H₂₇N₅O₂, MW 417.52). For cell-based assays, dissolve in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL with gentle warming/sonication). For in vivo studies, formulate according to animal protocol requirements; typical oral doses are 10–50 mg/kg in rodent models. Store powder at -20°C in a desiccated environment. Prepare working solutions fresh or store aliquots below -20°C for up to several months. For kinase or cell proliferation assays, titrate concentrations to define IC₅₀ under specific assay conditions. For angiogenesis or xenograft studies, include appropriate vehicle controls and confirm PDGFR pathway engagement by phosphorylation assays. Refer to the APExBIO CP-673451 product page for full specifications and handling protocols.

Conclusion & Outlook

CP-673451 (APExBIO) is a validated, highly selective ATP-competitive PDGFRα/β inhibitor with nanomolar potency. Its robust selectivity profile, in vivo efficacy, and detailed characterization make it a benchmark tool for elucidating PDGFR signaling in cancer research, especially in ATRX-deficient models. Ongoing research will further define its utility in combinatorial therapy screens and resistance mechanism studies. For further reading, consult recent peer-reviewed studies and the official product page.